Loading organizations...
Biovision Ventures is a venture capital firm specializing in early-stage life sciences and healthcare investments. It targets therapeutics, medtech, and bio-IT, supporting companies with strong intellectual property. Their strategy cultivates innovative scientific endeavors with transformative medical potential across the US and Europe.
Established in Luxembourg in 2017, Biovision Ventures was co-founded by Managing Partner Alexey Konov, PhD, and Partner Igor Gonikhin, CFA. Konov brought extensive prior experience in life sciences venture funds. The firm’s genesis stemmed from the need for specialized capital to translate groundbreaking scientific discoveries into clinical realities.
Biovision Ventures supports early-stage companies developing novel solutions in therapeutics, digital health, and medical technologies. The firm fosters transformative therapies addressing significant unmet medical needs. Their vision centers on driving life sciences innovation to improve global health outcomes by empowering scientific entrepreneurs.
Biovision Ventures has 3 tracked investments across 3 companies. The latest tracked deal is $125.0M Series B in Diagonal Therapeutics in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 9, 2026 | Diagonal Therapeutics | $125.0M Series B | Janus Henderson Investors, Paulina Hill | Atlas Venture, Balyasny Asset Management, BVF Partners, Checkpoint Capital, Deep Track Capital, EcoR1 Capital, Frazier Life Sciences, Lightspeed Venture Partners, Logos Capital, RA Capital Management, RV Invest, Velosity Capital, Viking Global Investors |
| May 1, 2024 | Radar Therapeutics | $13.0M Seed | — | Angelic Ventures, Arizona Tech Investors, B Capital Group, Endeavor Venture Funds, ExSight Capital Management, IVP, NFX, Pioneer Fund, Prithvi Ventures, Chris Gibson, Bevc, ELI Lilly And Company, KDT Ventures, Pear VC |
| Jun 23, 2022 | Elucid | $27.0M Series B | — | BlueStone Venture Partners, Bold Brain Ventures, IAG Capital Partners, John Fichthorn |
